...Adlumiz anamorelin from Helsinn Healthcare S.A.; Lynspad α-1 proteinase inhibitor, known elsewhere as Prolastin-C from Grifols S.A....
...Sciences Inc. Daiichi Pharmaceutical Co. Ltd. Ono Pharmaceutical Co. Ltd. Torii Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. Helsinn Healthcare S.A. Grifols S.A. BioCryst...

...Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) study to treat hospitalized COVID-19 patients. Emergent BioSolutions Inc. (NYSE:EBS), Grifols S.A....
...Inc. U.S. Defense Advanced Research Projects Agency Gilead Sciences Inc. The European Commission Johnson & Johnson NIH National Cancer Institute Emergent BioSolutions Inc. Grifols S.A. Takeda...

...candidates are in Phase I for various cancers.Grifols...
...total of $146 millionSpanish plasma-derived therapy company Grifols S.A....
...a co-development and commercialization deal that gave Grifols...

...On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced...
...U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their COVID-19 countermeasures. Grifols S.A....
...the plasma into hyperimmune globulin and support preclinical and clinical studies evaluating the therapy’s efficacy. Grifols...

...four scales, the trial's secondary endpoints. The plasma protein fraction, which Alkahest is developing with Grifols S.A....
...Wong, Staff Writer AKST6019 (GRF6019, ALK6019) DNL758 Emgality, galcanezumab-gnlm (LY2951742) ensifentrine (RPL554, VMX554, VRP554) SQX770 Alkahest Inc. Denali Therapeutics Inc. Eli Lilly and Co. Grifols S.A. Sanofi Squarex...

...is already partnered with Grifols S.A. under a 2015 co-development and commercialization deal. Nikolich said that Grifols...
...Summit, N.J. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Grifols S.A....

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....